HighMark Wealth Management LLC grew its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Free Report) by 119.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,269 shares of the company’s stock after purchasing an additional 11,588 shares during the quarter. Reata Pharmaceuticals […]
888 reiterated their reiterates rating on shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) in a research report released on Wednesday, Benzinga reports. RETA has been the subject of several other research reports. LADENBURG THALM/SH SH raised their price objective on shares of Reata Pharmaceuticals from $104.00 to $122.00 in a research note on Thursday. […]
Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its target price lifted by stock analysts at LADENBURG THALM/SH SH from $104.00 to $122.00 in a research note issued on Thursday, The Fly reports. LADENBURG THALM/SH SH’s price target points to a potential upside of 23.44% from the stock’s current price. Several other analysts also recently weighed […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) – Stock analysts at SVB Leerink upped their FY2024 earnings per share (EPS) estimates for shares of Reata Pharmaceuticals in a research report issued to clients and investors on Monday, June 12th. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings per share of […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) SVP Andrea Loewen sold 6,750 shares of the business’s stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $86.26, for a total transaction of $582,255.00. Following the transaction, the senior vice president now directly owns 32,007 shares in the company, […]